Author/Authors :
Białek, Łukasz First Department of Urology - Centre of Postgraduate Medical Education - Warsaw - Poland , Poletajew, Sławomir Second Department of Urology - Centre of Postgraduate Medical Education - Warsaw - Poland , Niemczyk, Michał Department of General - Oncological and Functional Urology - Medical University of Warsaw - Warsaw - Poland First Department of Urology - Centre of Postgraduate Medical Education - Warsaw, Poland , Czerwińska, Katarzyna Department of Transplantation Medicine - Nephrology and Internal Diseases - Medical University of Warsaw - Warsaw, Poland , Nowak, Mateusz Department of Urology - Tarnów - Poland , Sadowska, Anna Department of Transplantation Medicine - Nephrology and Internal Diseases - Medical University of Warsaw - Warsaw, Poland , Borkowski, Tomasz Department of General - Oncological and Functional Urology - Medical University of Warsaw - Warsaw - Poland First Department of Urology - Centre of Postgraduate Medical Education - Warsaw, Poland , Radziszewski, Piotr Department of General - Oncological and Functional Urology - Medical University of Warsaw - Warsaw - Poland First Department of Urology - Centre of Postgraduate Medical Education - Warsaw, Poland , Dobruch, Jakub First Department of Urology - Centre of Postgraduate Medical Education - Warsaw - Poland , Kryst, Piotr Second Department of Urology - Centre of Postgraduate Medical Education - Warsaw - Poland
Abstract :
Purpose: Human Kidney Injury Molecule-1 (hKIM-1) was proposed as urinary biomarker of renal cell carcinoma (RCC). The aim of the study was to validate urinary hKIM-1 as a biomarker of RCC.
Material and methods: Forty-six participants were enrolled into the study, including 30 patients with clear-cell or papillary RCC and 16 matched patients in the comparison group. Preoperative urinary hKIM-1 levels were measured
using commercially available ELISA kit and normalized to urinary creatinine levels.
Results: The concentrations of urinary hKIM-1 normalized to urinary creatinine in patients with RCC and comparison
group did not differ significantly (1.35 vs. 1.32 ng/mg creatinine, p = .25). There was also no difference
in urinary hKIM-1 concentration regarding stage or grade of renal cancer. Additional analysis of patients without
chronic kidney disease (defined as eGFR ≥ 60mL/min/1.73m²) also did not reveal significant difference in urinary
hKIM-1 concentrations between the groups (1.54 vs. 1.37; p = .47).
Conclusion: Results of our study do not confirm recent suggestions that urinary hKIM-1 may be a biomarker of RCC.
Keywords :
hKIM-1 , biomarker , kidney cancer , diagnosis , urine
